Myasthenia gravis (MG), an autoimmune disorder causing muscle weakness, frequently affects young adult women during their reproductive years. The safety of pregnancy for women with MG is a recurring clinical question, with implications for prenatal care and medication management. A recent narrative review highlights that while MG is rare in pregnancy, exacerbations are most common during the first trimester and the postpartum period, necessitating careful monitoring and drug adjustments.1
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness due to autoantibodies targeting acetylcholine receptors (AChR) or muscle-specific kinase (MuSK).1 Generalized MG is a more severe form than ocular MG.1 Although MG can manifest at any age, it commonly affects young adult women during their reproductive years.1
Myasthenia Gravis in Pregnancy: A Narrative Review
A narrative review published in Diagnostics (Basel) in 2026 examined the challenges of myasthenia gravis in pregnancy, focusing on prenatal and postnatal diagnostic considerations.1 The review identified that MG is rare during pregnancy, with exacerbations most frequently occurring in the first trimester and the postpartum period.1
The influence of MG on pregnancy outcomes remains ambiguous.1 Some studies have indicated a higher prevalence of issues such as preterm birth and small-for-gestational-age babies, while other studies suggest outcomes similar to the general population.1
Management of MG during pregnancy requires careful monitoring and drug adjustments.1 Certain immunosuppressive drugs, including mycophenolate mofetil and methotrexate, are contraindicated due to teratogenic concerns.1 In contrast, medications such as prednisolone and pyridostigmine are generally considered safe for use during pregnancy.1
Women with MG may experience flare-ups after giving birth.1 Additionally, infants born to mothers with MG may develop transient neonatal myasthenia gravis.1 The review emphasizes that comprehensive prenatal treatment and multidisciplinary assistance are crucial for promoting maternal and fetal health in women with MG during pregnancy.1
The paper also discusses the relevance of immunological biomarkers, RNAs, and other novel biomarkers in MG.1 It highlights the need for further investigation to determine their role in MG pathogenesis, evaluate biomarker profiles across subgroups, and observe changes after treatment.1 The study also underscores the significance of high-throughput investigations to identify new biomarkers and reveal genetic variables impacting MG pathogenesis.1
The persistent ambiguity regarding pregnancy outcomes for women with myasthenia gravis, as highlighted by this review, presents a practical challenge for clinicians. While some studies point to increased risks like preterm birth, the lack of consistent data means that individual patient counseling must remain highly nuanced. Relying on general population outcomes for reassurance, when specific risks are still debated, is a disservice to patients and potentially overlooks subtle but significant complications. The emphasis on multidisciplinary care is not merely a recommendation; it is a necessity given the complexities of managing an autoimmune condition during pregnancy and the postpartum period.
The clear distinction between contraindicated and safe medications during pregnancy (e.g., mycophenolate mofetil vs. prednisolone) is a critical piece of information that should be front-of-mind for any prescribing physician. The potential for transient neonatal myasthenia gravis also mandates close collaboration between neurologists, obstetricians, and neonatologists. This is not a condition where a single specialist can operate in isolation. The industry, particularly pharmaceutical companies developing new immunosuppressants, should prioritize robust reproductive safety data early in development, rather than leaving clinicians to extrapolate from limited evidence or rely on post-market surveillance.
Patients with MG contemplating pregnancy require transparent, evidence-based discussions about potential risks and the intensive monitoring required. The review's call for more research into biomarkers and genetic variables is a long-term goal, but for now, the focus must remain on optimizing current management strategies. The fact that exacerbations are most common in the first trimester and postpartum period provides actionable intelligence, allowing for proactive monitoring and intervention during these vulnerable windows. This is where clinical vigilance can make a tangible difference in maternal and neonatal outcomes.
- The Pivot MG exacerbations are most common in the first trimester and postpartum period, requiring vigilant monitoring.
- The Data Some studies report higher rates of preterm birth and small-for-gestational-age babies, though other studies show outcomes similar to the general population.
- The Action Clinicians should prioritize comprehensive prenatal treatment and multidisciplinary support, adjusting medications to avoid teratogenic drugs like mycophenolate mofetil and methotrexate.
ART-2026-105
Cite This Article
Team TLSFE. Myasthenia gravis in pregnancy: exacerbations common in peripartum. The Life Science Feed. Updated May 27, 2026. Accessed May 27, 2026. https://thelifesciencefeed.com/obstetrics-and-gyn/pregnancy-complications/myasthenia-gravis-in-pregnancy-exacerbations-common-in-peripartum.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Gerede A, Danavasi M, Oikonomou E. Myasthenia Gravis in Pregnancy: Prenatal and Postnatal Diagnostic Challenges-A Narrative Review. Diagnostics (Basel). 2026;16(2):123. doi:10.3390/diagnostics16020123